한미약품은 창조와 도전을 기치로 신약개발에 매진하는 R&D중심 제약기업입니다.
The Paltan plant has the largest production capacity for solid dosages in Korea. It has over 500 employees, including 45 researchers in the formulation development division. Advanced research on drug delivery systems (IMD) and new drug formulations are a part of the Paltan plant's greater scheme of achievements and responsibility.
The Paltan GMP plant was established in 1984 and accredited by KGMP in 1986. In 1995, its “microemulsion technology” was transferred to Novartis. In 2009, it was granted EU GMP certification from the German authority (BGV) and re-inspected in 2012. It was also recently granted ANVISA certification in 2013.
The Paltan plant is a 3-story construction, with its first and second floor dedicated to production and its third floor dedicated to drug research and quality management. Its 4,000 m2 depot is equipped with state-of-art automated warehousing system. Plans are underway to expand its 9,640 pallet capability to 16,950 pallets to accommodate the plant's growing operations.